Maxime Verhoeven

97 TCZ vs. TCZ+MTX; prevention of radiographic progression in RA Supplementary Table S4 Comparative effects of different TCZ-regimens on preventing radiographic progression in established RA, results of mixed model analysis. total SvdH Erosions JSN Relative Risk (95%CI) Relative Risk (95%CI) Relative Risk (95%CI) TCZ vs. TCZ+MTX* Treatment (TCZ) 0.85 (0.44 to 1.66) 1.02 (0.50 to 2.07) 0.69 (0.35 to 1.37) Baseline DAS28 1.00 (0.81 to 1.24) 1.05 (0.83 to 1.31) 0.94 (0.75 to 1.18) Disease duration (years) 0.99 (0.94 to 1.03) 1.02 (0.97 to 1.08) 1.02 (0.98 to 1.07) Baseline SvdH 1.01 (0.99 to 1.02) 1.00 (0.98 to 1.01) 0.99 (0.98 to 1.00) Gender (female) 1.94 (1.14 to 3.29) 2.20 (1.29 to 3.75) 1.00 (0.57 to 1.73) Age 1.00 (0.98 to 1.01) 0.99 (0.98 to 1.01) 1.00 (0.98 to 1.02) Baseline SvdH * treatment 0.99 (0.97 to 1.00) 0.99 (0.98 to 1.01) 0.99 (0.98 to 1.01) Disease duration (years) * treatment 1.07 (1.00 to 1.14) 1.02 (0.95 to 1.09) 1.06 (0.99 to 1.14) Number of patients is 202 in TCZ and 215 in TCZ+MTX. TCZ= tocilizumab; MTX= methotrexate; DAS28= disease activity score assessing 28 joints; SvdH= Sharp van der Heijde; JSN= joint space narrowing Outcome variable is not having radiographic progression over 2 years (yes/no), intercept for models (regression coefficient) for total SvdH -0.70 (95%CI -2.26 to 1.26); for erosions -0.54 (95%CI -2.60 to 1.52); for JSN 1.43 (95%CI -1.26 to 4.12). P-value for interaction term Baseline SvdH * treatment based on total SvdH score: TCZ vs. TCZ+MTX [p=0.08]. P-value for interaction termDisease duration * treatment based on total SvdH score: TCZ vs. TCZ+MTX [p=0.04]. 5